Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

George Taffet

Geriatric Medicine Houston, TX Medical Doctor

NPI 1740360080 CMS profile 351024

6620 Main St, Houston, TX 77030

Open in the dashboard

General payments

$8,746

16 records reported · program years 2019–2025

Research payments

$50

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, George Taffet of Houston, TX is reported in the CMS Open Payments database as having received $8,746 across 16 general payments and $50 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Geriatric Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $27 1
2023 General $18 1
2022 General $6,619 5
2021 General $1,960 2
2021 Research $50 1
2020 General $13 1
2019 General $109 6

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • George Taffet
  • Geriatric Medicine median
  • Middle half of Geriatric Medicine
  • National median

In program year 2025, general payments to George Taffet were reported at $27. Among 1,028 Geriatric Medicine profiles paid that year, the median was $123 and the middle half received between $35 and $408.

Show as a table
Year George Taffet Geriatric Medicine median Middle half National median
2019 $109 $122 $40–$435 $163
2020 $13 $98 $25–$349 $114
2021 $1,960 $125 $34–$441 $132
2022 $6,619 $124 $36–$408 $149
2023 $18 $121 $41–$383 $160
2024 $0 $134 $41–$435 $164
2025 $27 $123 $35–$408 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Eli Lilly and Company $5,400 1 payment
  2. Novartis Pharmaceuticals Corporation $1,960 2 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $1,202 3 payments
  4. Merck Sharp & Dohme Corporation $68 5 payments
  5. Sunovion Pharmaceuticals Inc. $44 1 payment
  6. Alexion Pharmaceuticals, Inc. $33 2 payments
  7. Madrigal Pharmaceuticals $27 1 payment
  8. Pfizer Inc. $11 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $5,400 1 payment
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $1,960 2 payments
  3. Travel and Lodging $1,164 2 payments
  4. Food and Beverage $222 11 payments
Products named General payments · program years 2019–2025
  1. JARDIANCE $1,202 3 payments
  2. ZERBAXA $68 5 payments
  3. APTIOM $44 1 payment
  4. REZDIFFRA $27 1 payment
  5. RECARBRIO $18 1 payment
  6. DIFICID $18 1 payment
  7. Ultomiris $16 1 payment
  8. PREVNAR - 13 $11 1 payment
  9. SIVEXTRO $11 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Eli Lilly and Company $50 1 payment

Billing to Medicare

Part B · data year 2024 · 11 billing codes

Paid by Medicare

$79,647

Medicare's payments for the services billed

Medicare patients

169

Average age 84

Services billed

994

88 women, 81 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Alzheimer's or dementia 75%
Chronic kidney disease 64%
Ischemic heart disease 63%
Arthritis 58%
Heart failure 57%
Depression 47%
Atrial fibrillation 45%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

17 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Geriatric Medicine in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record